AI can now do more than write code—it’s about to invent life-saving drugs! According to the authoritative tech media The Verge today, Anthropic, the developer of the renowned AI model Claude, has made a startling announcement: in addition to launching an AI workspace for scientific research, the company is officially entering the physical pharmaceutical industry, focusing on developing cures for "neglected diseases." This means Anthropic could transform from a mere software provider into a potential competitor to major pharmaceutical companies. However, experts have tempered expectations: AI-developed drugs still face at least a decade of clinical trials before they can receive FDA approval and reach patients.
(Prior context: Anthropic poured $100,000 into a hackathon, testing Claude Science with real scientific data)
(Background: Challenging Nvidia's Dominance! Anthropic Reportedly Partners with Samsung to Develop Custom AI Chips, Overhauling Claude's Computing Foundation)
At the crossroads where artificial intelligence and life sciences are accelerating their convergence, the San Francisco-based AI giant Anthropic has chosen the most difficult, yet most ambitious path.
This week, at Anthropic’s event “The Briefing: AI for Science,” the company first showcased Claude Science — a new “AI workbench” designed for leading scientists. It integrates scattered research tools and vast datasets into a single environment and automatically generates complex visualizations, aiming to significantly accelerate scientific discovery and medical interventions.
However, what truly shocked the industry was the major announcement in the latter half of the presentation.
From selling shovels to mining themselves, Anthropic enters the physical pharmaceutical industry
Eric Kauderer-Abrams, Head of Anthropic’s Life Sciences division, announced at the event that the company will move beyond merely “providing AI tools to pharmaceutical companies” and will directly develop drugs itself, with initial R&D efforts focused on neglected diseases—conditions that lack commercial profitability and are rarely targeted by traditional pharmaceutical firms.
This decision makes Anthropic stand out in the tech industry. While OpenAI, Google, and Amazon have all launched tools related to life sciences, very few leading AI model developers have dared to publicly announce they will develop physical drugs themselves. This means Anthropic will, on one hand, sell Claude to major pharmaceutical companies, while on the other, potentially become their direct competitor in specific disease areas.
AI Drug Development: The Ambitions of Tech Companies vs. The Harsh Reality of Medicine
Although Silicon Valley is optimistic about AI revolutionizing the pharmaceutical industry, multiple leading scholars and experts interviewed noted a significant real-world gap between computational models and actual life-saving treatments.
| Observation dimension | Current Status and Layout of the Technology Industry | Realistic warnings from medical experts |
|---|---|---|
| Shift in development model | Anthropic is actively recruiting biologists and has established a dedicated physical facility called a "wet lab." | AI excels at accelerating the initial "search" for candidate molecules, but the entire drug development process still requires strict oversight and experimental validation by human experts. |
| Clinical Trials and Regulations | Several startups (such as Insilico) have AI-assisted candidate drugs in clinical trials. | Currently, no drug entirely designed by AI has successfully completed full clinical trials and received FDA approval for market release. |
| Time and data bottlenecks | Expecting to generate a perfect drug formulation with one click using a large language model (LLM). | Lack of high-quality public experimental data; and it still takes at least 10 years from discovering a new target to final market approval. |
Expert: AI cannot replace lab rats
Professor Frank von Delft of Oxford University bluntly points out that AI is still far from replacing physical experiments. Even if AI can perfectly predict the structure of an entirely new molecule, the candidate drug must still undergo testing for toxicity, stability, and in vivo efficacy in the real world. These preclinical and clinical trials require hundreds of millions of dollars and have alarmingly high failure rates.
Professor Matthew Todd from University College London’s Drug Discovery also added that although AI has great potential for rapidly testing new drug ideas, chemical reactions within living organisms are extremely complex, and significant knowledge gaps remain in many areas of medicine that algorithms alone cannot fill.
Currently, Anthropic has not disclosed the specific disease target for its first candidate drug, nor has it clarified whether it plans to proceed independently or collaborate with traditional pharmaceutical companies during clinical trials and manufacturing. However, it is undeniable that this AI giant, valued at tens of billions of dollars, has taken its most challenging step toward its ambitious life sciences vision.
📍Related Articles📍
Anthropic's new Mythos training is complete, and Sonnet 5 is set to be released this week.